TG Therapeutics (TGTX) to Release Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is projected to issue its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect the company to announce earnings of $0.24 per share and revenue of $152.1150 million for the quarter. TG Therapeutics has set its FY 2025 guidance at EPS.Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.15). The firm had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The firm’s revenue was up 92.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.04 EPS. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

TG Therapeutics Trading Down 0.5%

Shares of NASDAQ:TGTX opened at $33.33 on Monday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The stock’s 50-day moving average is $32.87 and its 200-day moving average is $34.94. The company has a market cap of $5.29 billion, a P/E ratio of 90.08 and a beta of 1.97. TG Therapeutics has a 52-week low of $22.92 and a 52-week high of $46.48.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. The Goldman Sachs Group upgraded TG Therapeutics to a “hold” rating and set a $37.00 target price for the company in a research note on Thursday, July 10th. B. Riley upped their price target on TG Therapeutics from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of TG Therapeutics in a research report on Saturday. Finally, HC Wainwright assumed coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 target price for the company. Four research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $49.00.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 20,852 shares of the firm’s stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $32.24, for a total value of $672,268.48. Following the completion of the transaction, the director directly owned 94,061 shares of the company’s stock, valued at $3,032,526.64. This trade represents a 18.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.64% of the company’s stock.

Institutional Investors Weigh In On TG Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Corient Private Wealth LLC raised its holdings in shares of TG Therapeutics by 98.2% in the 2nd quarter. Corient Private Wealth LLC now owns 80,704 shares of the biopharmaceutical company’s stock worth $2,905,000 after buying an additional 39,987 shares in the last quarter. Boothbay Fund Management LLC raised its stake in TG Therapeutics by 16.3% during the second quarter. Boothbay Fund Management LLC now owns 71,051 shares of the biopharmaceutical company’s stock worth $2,557,000 after acquiring an additional 9,963 shares in the last quarter. Brevan Howard Capital Management LP lifted its holdings in shares of TG Therapeutics by 36.4% during the second quarter. Brevan Howard Capital Management LP now owns 60,120 shares of the biopharmaceutical company’s stock valued at $2,164,000 after acquiring an additional 16,047 shares during the period. Sei Investments Co. lifted its holdings in TG Therapeutics by 60.4% during the 2nd quarter. Sei Investments Co. now owns 47,592 shares of the biopharmaceutical company’s stock valued at $1,713,000 after purchasing an additional 17,930 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in TG Therapeutics by 23.6% in the second quarter. E Fund Management Co. Ltd. now owns 21,009 shares of the biopharmaceutical company’s stock valued at $756,000 after buying an additional 4,013 shares in the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.